Figure 9. PCA-verified biomarkers predict the seizure severity.
(A) Representative EEG recordings from the ipsilateral hippocampus showing three examples of identified seizure-like episodes. Scale bars: Horizontal 5 s, vertical 2 mV. (B) Quantitative analysis of seizure-like episodes for individual epileptic mice (color-coded; note that EEG data is lacking for NP26). One-way ANOVA, Bonferroni’s post-test, *p<0.05, **p<0.01, number of recordings: nNP27 = 5, nNP11 = 7, nNP31 = 5, nNP14 = 4, nNP34 = 5, nNP25 = 7. Values are presented as the mean ± SEM. (C) Pearson’s correlation analysis of PC1 scores and the frequency of seizure-like episodes (n = 6).
Figure 9—figure supplement 1. Experimental design to translate MRI biomarkers into the clinic.
Schematic illustrating an outline for the clinical translation of experimentally-identified biomarkers. Multimodal MRI is repeatedly applied early after the initial precipitating injury (IPI) until the onset of clinical seizures. Cross-correlation and PCA identifies interconnected MRI parameters and validates their predictive value with respect to MRI-identified HS and seizure onset in chronic mTLE. Subsequently, the change of MRI metrics (d) early after IPI can be assigned to the probability (p) of epilepsy onset and severity. Most robust MRI biomarkers can then be routinely used in clinics to prognose acquired mTLE, which allows to start anti-epileptogenic treatment early before clinical manifestation of epilepsy.